{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:47:23Z","timestamp":1776919643263,"version":"3.51.2"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ewing\u2019s sarcoma (ES) is the second most common malignant bone tumor in patients under 20 years of age. The \u201cEuro-Ewing 2012\u201d trial established induction therapy with the 2-week-interval VDC\/IE (Vincristine-Doxorubicine-Cyclophosphamide\/Ifosfamide-Etoposide) as the standard of care. However, real-world data remain limited. We aimed to determine the feasibility, tolerance, and effectiveness of this protocol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective, single-institutional cohort study, including patients with ES treated between January 2018 and April 2024 using the interval-compressed VDC\/IE protocol. Data were collected on feasibility, toxicity, and outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 27 patients. Median age at diagnosis was 18.3 years. Sekeletal tumors predominated (89%), mainly in the pelvis and lower limbs. Metastatic disease was present at diagnosis in 41%. Neoadjuvant chemotherapy was initiated after a median delay of 36 days post-biopsy, with a median duration of 22 weeks and a mean interval of 19.8 days. The mean relative dose intensity (RDI) was 70%, with only 11% of patients achieving an RDI &amp;gt;85%. A lower RDI was observed in adults (p=0.011) and metastatic stage patients (p=0.011). High-grade toxicities were reported in 89% of patients, primarily neutropenia. Good pathologic response was reported in 11 patients. After a median follow-up of 26 months, the median OS was 32 months, with 3-year OS and EFS rates of 36.9% and 19.9%, respectively. The relapse rate was 67%, with a median relapse time of 13 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study highlights the challenges of implementing the EE2012 protocol in our practice. Adapting the regimen could optimize induction, particularly for localized forms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1710836","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:20:55Z","timestamp":1776918055000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Interval-compressed chemotherapy in patients with Ewing\u2019s sarcoma: report on feasibility and toxicity from a North African center"],"prefix":"10.3389","volume":"16","author":[{"given":"Nesrine","family":"Kooli","sequence":"first","affiliation":[{"name":"Medical Oncology Department, Institut Salah Azaiz","place":["Tunis, Tunisia"]},{"name":"Medical Faculty of Tunis, Tunis El Manar University","place":["Tunis, Tunisia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajer","family":"Ben Mansour","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Institut Salah Azaiz","place":["Tunis, Tunisia"]},{"name":"Medical Faculty of Tunis, Tunis El Manar University","place":["Tunis, Tunisia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosr","family":"Zenzri","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Institut Salah Azaiz","place":["Tunis, Tunisia"]},{"name":"Medical Faculty of Tunis, Tunis El Manar University","place":["Tunis, Tunisia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoldez","family":"Houcine","sequence":"additional","affiliation":[{"name":"Medical Faculty of Tunis, Tunis El Manar University","place":["Tunis, Tunisia"]},{"name":"Pathology Department B, Institut Salah Azaiz","place":["Tunis, Tunisia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amina","family":"Mokrani","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Institut Salah Azaiz","place":["Tunis, Tunisia"]},{"name":"Medical Faculty of Tunis, Tunis El Manar University","place":["Tunis, Tunisia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khedija","family":"Meddeb","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Institut Salah Azaiz","place":["Tunis, Tunisia"]},{"name":"Medical Faculty of Tunis, Tunis El Manar University","place":["Tunis, Tunisia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salma","family":"Kamoun","sequence":"additional","affiliation":[{"name":"Medical Faculty of Tunis, Tunis El Manar University","place":["Tunis, Tunisia"]},{"name":"Pathology Department B, Institut Salah Azaiz","place":["Tunis, Tunisia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mouna","family":"Ayadi","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Institut Salah Azaiz","place":["Tunis, Tunisia"]},{"name":"Medical Faculty of Tunis, Tunis El Manar University","place":["Tunis, Tunisia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nesrine","family":"Chraiet","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Institut Salah Azaiz","place":["Tunis, Tunisia"]},{"name":"Medical Faculty of Tunis, Tunis El Manar University","place":["Tunis, Tunisia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henda","family":"Rais","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Institut Salah Azaiz","place":["Tunis, Tunisia"]},{"name":"Medical Faculty of Tunis, Tunis El Manar University","place":["Tunis, Tunisia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e31816e22f3","article-title":"Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data","volume":"30","author":"da Silva","year":"2008","journal-title":"J Pediatr Hematol Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33674","article-title":"Comparative international incidence of Ewing sarcoma 1988 to 2012","volume":"149","author":"Lg","year":"2021","journal-title":"Int J Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114229","article-title":"Impact of age on safety of Busulfan-Melphalan followed by autologous hematopoietic stem-cell transplantation versus standard chemotherapy in the patients of the EURO-E.W.I.N.G. 99 and Ewing 2008 clinical trials","volume":"208","author":"Choderlos de Laclos","year":"2024","journal-title":"Eur J Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.00358","article-title":"Phase III trial adding vincristine-topotecan-cyclophosphamide to the initial treatment of patients with nonmetastatic Ewing sarcoma: A Children\u2019s Oncology Group report","volume":"39","author":"Leavey","year":"2021","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25840","article-title":"Clinical features and outcomes in patients with extraskeletal Ewing sarcoma","volume":"117","author":"Applebaum","year":"2011","journal-title":"Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2014.12.012","article-title":"Prognostic factors for survival in patients with Ewing\u2019s sarcoma using the surveillance, epidemiology, and end results (SEER) program database","volume":"39","author":"Duchman","year":"2015","journal-title":"Cancer Epidemiol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.16.5720","article-title":"Results of the EICESS-92 study: two randomized trials of Ewing\u2019s sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients","volume":"26","author":"Paulussen","year":"2008","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2005.01.004","article-title":"Context matters: The hen or egg problem in Ewing\u2019s sarcoma","volume":"15","author":"Kovar","year":"2005","journal-title":"Semin Cancer Biol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1177\/1066896919893073","article-title":"Ewing sarcoma in older adults: A clinicopathologic study of 50 cases occurring in patients aged \u226540 years, with emphasis on histologic mimics","volume":"28","author":"Jahanseir","year":"2020","journal-title":"Int J Surg Pathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00053","article-title":"Long-term outcomes in patients with localized Ewing sarcoma treated with interval-compressed chemotherapy on Children\u2019s Oncology Group Study AEWS0031","volume":"41","author":"Cash","year":"2023","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.41.5703","article-title":"Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children\u2019s Oncology Group","volume":"30","author":"Womer","year":"2012","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/s0959-8049(97)00334-1","article-title":"Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing\u2019s sarcomas and soft tissue sarcomas in children","volume":"36","author":"Womer","year":"2000","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)01790-1","article-title":"Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial","volume":"400","author":"Brennan","year":"2022","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13063-019-4026-8","article-title":"International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours - EURO EWING 2012 protocol","volume":"21","author":"Anderton","year":"2020","journal-title":"Trials"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0463","article-title":"Localized adult Ewing sarcoma: Favorable outcomes with alternating vincristine, doxorubicin, cyclophosphamide, and ifosfamide, etoposide (VDC\/IE)-based multimodality therapy","volume":"22","author":"Pretz","year":"2017","journal-title":"Oncologist"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-85516-3_301","article-title":"Feasibility of treating adults with Ewing or Ewing\u2010like sarcoma with interval\u2010compressed vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide","volume":"25","author":"Lu","year":"2020","journal-title":"Oncologist"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(80)90472-6","article-title":"Dose: A critical factor in cancer chemotherapy","volume":"69","author":"Frei","year":"1980","journal-title":"Am J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1984.2.11.1281","article-title":"The importance of dose intensity in chemotherapy of metastatic breast cancer","volume":"2","author":"Hryniuk","year":"1984","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2003.09.081","article-title":"Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741\/Cancer and Leukemia Group B Trial 9741","volume":"21","author":"Citron","year":"2003","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2095","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22456","article-title":"Adjuvant and neoadjuvant chemotherapy for Ewing sarcoma family tumors in patients aged between 40 and 60: report of 35 cases and comparison of results with 586 younger patients treated with the same protocols in the same years","volume":"109","author":"Bacci","year":"2007","journal-title":"Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13998","article-title":"Association of chemotherapy dose intensity and age with outcomes in patients with Ewing\u2019s family sarcoma","volume":"21","author":"Klingberg","year":"2025","journal-title":"Asia Pac J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2024.102653","article-title":"Treatment differences and long-term outcomes in adults and children with Ewing sarcoma","volume":"92","author":"Hajjaj","year":"2024","journal-title":"Cancer Epidemiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.phoj.2023.10.038","article-title":"Safety and tolerability of interval compressed chemotherapy schedule in children receiving treatment for Ewings sarcoma - A real world experience from India","volume":"8","author":"Pal","year":"2023","journal-title":"Pediatr Hematol Oncol J"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13040668","article-title":"Feasibility and toxicity of interval-compressed chemotherapy in Asian children and young adults with sarcoma","volume":"13","author":"Huang","year":"2023","journal-title":"J Pers Med"},{"key":"B26","first-page":"295","article-title":"Principles of medical oncology","volume-title":"Cancer: principles and practice of oncology","author":"Chu","year":"2005"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197112)28:6<1479::aid-cncr2820280622>3.0.co;2-m","article-title":"Kinetics of mammary tumor cell growth and implications for therapy","volume":"28","author":"Skipper","year":"1971","journal-title":"Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"99","DOI":"10.6004\/jnccn.2009.0009","article-title":"Impact of chemotherapy dose intensity on cancer patient outcomes","volume":"7","author":"Lyman","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1991.9.2.339","article-title":"The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin\u2019s lymphoma","volume":"9","author":"Meyer","year":"1991","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1179\/joc.1997.9.5.352","article-title":"Prognostic factors in patients with localized Ewing\u2019s sarcoma: the effect on survival of actual received drug dose intensity and of histologic response to induction therapy","volume":"9","author":"Delepine","year":"1997","journal-title":"J Chemother Florence Italy"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20820","article-title":"Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial","volume":"47","author":"Juergens","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-012-1920-0","article-title":"Comparison of dose intensity of vincristine, d-actinomycin, and cyclophosphamide chemotherapy for child and adult rhabdomyosarcoma: a retrospective analysis","volume":"70","author":"Kojima","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2000.18.24.4028","article-title":"Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma","volume":"18","author":"Lewis","year":"2000","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1186\/s12885-019-6407-5","article-title":"Impact of chemotherapy cycles and intervals on outcomes of nonspinal Ewing sarcoma in adults: a real-world experience","volume":"19","author":"Zhang","year":"2019","journal-title":"BMC Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25144","article-title":"Clinical outcome of children and adults with localized Ewing sarcoma","volume":"116","author":"Gupta","year":"2010","journal-title":"Cancer"},{"key":"B36","article-title":"Tolerability and safety of vincristine, ifosfamide, doxorubicin and etoposide in adolescent and young adult patients with Ewing sarcoma","volume":"3","author":"Lau","year":"2019","journal-title":"SM J Sarcoma Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1200\/jco.2015.63.4048","article-title":"Intensive multiagent therapy, including dose-compressed cycles of ifosfamide\/etoposide and vincristine\/doxorubicin\/cyclophosphamide, irinotecan, and radiation, in patients with high-risk rhabdomyosarcoma: A report from the Children\u2019s Oncology Group","volume":"34","author":"Weigel","year":"2015","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27493","article-title":"Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients","volume":"118","author":"Longhi","year":"2012","journal-title":"Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ejca.2003.08.022","article-title":"Long-term outcome for patients with non-metastatic Ewing\u2019s sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992","volume":"40","author":"Bacci","year":"2004","journal-title":"Eur J Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25304","article-title":"Ovarian function in female survivors after multimodal Ewing sarcoma therapy","volume":"62","author":"Raciborska","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.11570","article-title":"Dose intensity and outcomes of VDC\/IE chemotherapy for adolescent and adult patients with Ewing\u2019s family sarcoma","volume":"40","author":"Klingberg","year":"2022","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4688","article-title":"Comorbidities rather than older age define outcome in adult patients with tumors of the Ewing sarcoma family","volume":"11","author":"Striefler","year":"2022","journal-title":"Cancer Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.43.8598","article-title":"Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis","volume":"31","author":"Collins","year":"2013","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27251","article-title":"Age dependency of primary tumor sites and metastases in patients with Ewing sarcoma","volume":"65","author":"Worch","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34942","article-title":"Consensus recommendations in the management of Ewing sarcoma from the National Ewing Sarcoma Tumor Board","volume":"129","author":"Gupta","year":"2023","journal-title":"Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2018.78.2516","article-title":"High-dose chemotherapy and blood autologous stem-cell rescue compared with standard chemotherapy in localized high-risk Ewing sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008","volume":"36","author":"Whelan","year":"2018","journal-title":"J Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.00915","article-title":"High-dose chemotherapy compared with standard chemotherapy and lung radiation in Ewing sarcoma with pulmonary metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008","volume":"37","author":"Dirksen","year":"2019","journal-title":"J Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.22.9864","article-title":"Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial","volume":"28","author":"Ladenstein","year":"2010","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2023.100482","article-title":"Molecular and biologic biomarkers of Ewing sarcoma: A systematic review","volume":"40","author":"Daher","year":"2023","journal-title":"J Bone Oncol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/s1470-2045(16)00162-5","article-title":"Survival of European adolescents and young adults diagnosed with cancer in 2000\u201307: population-based data from EUROCARE-5","volume":"17","author":"Trama","year":"2016","journal-title":"Lancet Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01367","article-title":"Survival trends among adolescents and young adults diagnosed with cancer in the United States: Comparisons with children and older adults","volume":"42","author":"Keegan","year":"2024","journal-title":"J Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.canep.2012.08.006","article-title":"Characteristics and outcomes of patients with Ewing sarcoma over 40 years of age at diagnosis","volume":"37","author":"Karski","year":"2013","journal-title":"Cancer Epidemiol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114209","article-title":"The survival disparity between children and adolescents and young adults (AYAs) with Ewing sarcoma in the Netherlands did not change since the 1990s despite improved survival: A population-based study","volume":"208","author":"Schulpen","year":"1990","journal-title":"Eur J Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0632-1","article-title":"Survival after cancer in children, adolescents and young adults in the Nordic countries from 1980 to 2013","volume":"121","author":"Rostgaard","year":"2019","journal-title":"Br J Cancer"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-020-02236-0","article-title":"Survival of childhood and adolescent\/young adult (AYA) cancer patients in Ireland during 1994-2013: comparisons by age","volume":"189","author":"Alken","year":"2020","journal-title":"Ir J Med Sci"},{"key":"B56","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s12891-018-2217-1","article-title":"Descriptive epidemiology and outcomes of bone sarcomas in adolescent and young adult patients in Japan","volume":"19","author":"Fukushima","year":"2018","journal-title":"BMC Musculoskelet Disord"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.12269","article-title":"Adolescents and young adults (AYAs) with initially localized and metastatic bone sarcomas: A retrospective single center analysis of side effect management","volume":"35","author":"Minichsdorfer","year":"2021","journal-title":"Vivo Athens Greece"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188606","article-title":"Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials","volume":"1876","author":"Tang","year":"2021","journal-title":"Biochim Biophys Acta BBA - Rev Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1710836\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:20:56Z","timestamp":1776918056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1710836\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":58,"alternative-id":["10.3389\/fonc.2026.1710836"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1710836","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]},"article-number":"1710836"}}